Compare ALEMBIC with Orchid Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs ORCHID PHARMA - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

ORCHID PHARMA 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC ORCHID PHARMA ALEMBIC/
ORCHID PHARMA
 
P/E (TTM) x 56.6 -23.6 - View Chart
P/BV x 4.9 6.8 72.3% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 ALEMBIC   ORCHID PHARMA
EQUITY SHARE DATA
    ALEMBIC
Mar-18
ORCHID PHARMA
Sep-13
ALEMBIC/
ORCHID PHARMA
5-Yr Chart
Click to enlarge
High Rs72194 37.1%   
Low Rs3435 96.9%   
Sales per share (Unadj.) Rs4.7276.5 1.7%  
Earnings per share (Unadj.) Rs6.1-79.2 -7.7%  
Cash flow per share (Unadj.) Rs6.2-43.5 -14.4%  
Dividends per share (Unadj.) Rs0.200-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs40.753.9 75.4%  
Shares outstanding (eoy) m267.0370.45 379.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x11.30.4 2,719.9%   
Avg P/E ratio x8.7-1.4 -600.1%  
P/CF ratio (eoy) x8.5-2.6 -321.7%  
Price / Book Value ratio x1.32.1 61.3%  
Dividend payout %3.30-   
Avg Mkt Cap Rs m14,1398,067 175.3%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m2072,527 8.2%   
Avg. sales/employee Rs ThNM6,956.1-  
Avg. wages/employee Rs ThNM902.5-  
Avg. net profit/employee Rs ThNM-1,993.0-  
INCOME DATA
Net Sales Rs m1,25519,477 6.4%  
Other income Rs m370407 90.9%   
Total revenues Rs m1,62519,884 8.2%   
Gross profit Rs m1111,103 10.1%  
Depreciation Rs m382,519 1.5%   
Interest Rs m25,227 0.0%   
Profit before tax Rs m442-6,236 -7.1%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m24-125 -19.1%   
Profit after tax Rs m1,630-5,580 -29.2%  
Gross profit margin %8.95.7 156.4%  
Effective tax rate %5.42.0 270.0%   
Net profit margin %129.8-28.7 -453.2%  
BALANCE SHEET DATA
Current assets Rs m1,86711,014 17.0%   
Current liabilities Rs m59132,060 1.8%   
Net working cap to sales %101.6-108.1 -94.1%  
Current ratio x3.20.3 919.3%  
Inventory Days Days9495 99.3%  
Debtors Days Days7434 219.2%  
Net fixed assets Rs m1,79129,440 6.1%   
Share capital Rs m534705 75.8%   
"Free" reserves Rs m10,3242,043 505.4%   
Net worth Rs m10,8583,800 285.7%   
Long term debt Rs m419,018 0.5%   
Total assets Rs m11,59146,510 24.9%  
Interest coverage x260.9-0.2 -135,088.2%   
Debt to equity ratio x02.4 0.2%  
Sales to assets ratio x0.10.4 25.9%   
Return on assets %14.1-0.8 -1,852.1%  
Return on equity %15.0-146.9 -10.2%  
Return on capital %15.2-3.7 -406.7%  
Exports to sales %1.537.9 4.1%   
Imports to sales %21.022.6 92.7%   
Exports (fob) Rs m197,378 0.3%   
Imports (cif) Rs m2634,406 6.0%   
Fx inflow Rs m197,513 0.3%   
Fx outflow Rs m2645,649 4.7%   
Net fx Rs m-2441,865 -13.1%   
CASH FLOW
From Operations Rs m2361,682 14.0%  
From Investments Rs m-224-9,860 2.3%  
From Financial Activity Rs m-276,644 -0.4%  
Net Cashflow Rs m-15-1,535 1.0%  

Share Holding

Indian Promoters % 64.0 32.3 198.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 4.6 4.3%  
FIIs % 9.7 3.3 293.9%  
ADR/GDR % 0.0 4.6 -  
Free float % 26.1 55.3 47.2%  
Shareholders   54,701 84,811 64.5%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   SANOFI INDIA  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ABBOTT INDIA  

Compare ALEMBIC With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 531 Points; Reliance Industries & IndusInd Bank Fall 5%(Closing)

Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (3QFY19); Net Profit Down 41.9% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, ALEMBIC LTD has posted a net profit of Rs 32 m (down 41.9% YoY). Sales on the other hand came in at Rs 243 m (down 18.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


Jan 25, 2021 (Close)

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE ALEMBIC WITH

MARKET STATS